ASIA-PACIFIC MALE INFERTILITY MARKET FORECAST 2023-2032

The Asia-Pacific male infertility market growth assessment includes the analysis of Australia & New Zealand, South Korea, Thailand, Vietnam, Japan, China, India,  Indonesia, and Rest of Asia-Pacific. The male infertility market in China is poised for rapid expansion due to various factors. The increased prevalence of diseases such as diabetes, genetic abnormalities, and infections like chlamydia, gonorrhea, mumps, and HIV is anticipated to drive market growth. China’s persistent rise in male infertility cases and the widespread adoption of Assisted Reproductive Technology (ART) will further expand market growth. 

However, the increasing prevalence of diabetes, projected to reach 9.7% among Chinese adults aged 20-79 by 2030, may negatively impact fertility rates. Furthermore, the brucella bacterial infection outbreak in China, which causes male infertility, is also favorably influencing the market. These factors collectively indicate a promising growth trajectory for the male infertility market in China during the forecast period.

The male infertility market in Japan is poised for growth in the forecast period due to several key factors. One contributing factor is the high rate of smoking and unhealthy lifestyle habits prevalent in the population. According to the World Health Organization Framework Convention on Tobacco Control, Japan’s smoking rate was 18.2% in 2020, with 30.1% of Japanese men being smokers. This historically high percentage of smokers can adversely affect sperm counts and increase the risk of erectile dysfunction among men. 

Consequently, the demand for male infertility treatments is expected to rise, driving market expansion. Additionally, the adoption of assisted reproductive technologies, the availability of reimbursements and insurance for couples seeking such treatments, and other factors will also contribute to the growth of the male infertility market in Japan.

The Asia-Pacific male infertility market segmentation entails the evaluation by test type and treatment. Market by test type covers microscopic examination, DNA fragmentation technique, sperm agglutination, oxidative stress analysis, computer-assisted semen analysis, sperm penetration assay, and other test types.

The DNA fragmentation technique serves as an effective means to detect male infertility, where changes in nucleotide composition or physical breaks occur in one or both sperm chromosomes. Studies indicate that infertile males are more prone to sperm DNA damage, leading to unfavorable reproductive outcomes. 

Consequently, the DNA fragmentation approach holds promise as a novel method for fertility evaluation. In specific clinical scenarios, sperm DNA fragmentation (SDF) tests are used as complementary assessments alongside traditional semen analysis. With its wide acceptance and diagnostic capabilities in assessing sperm DNA integrity, the DNA fragmentation technique is anticipated to witness robust growth in the coming years. 

Factors such as clinical diseases, environmental exposures, lifestyle risks, and innovations in testing methods contribute to the market’s expansion. Notably, Legacy, an online male reproductive clinic, introduced the first consumer-friendly at-home sperm DNA fragmentation (SDF) analysis in 2021, further enhancing market potential.

Key players operating in the Asia-Pacific male infertility market include Zydus Lifesciences Ltd (Cadila Healthcare Ltd), Bayer Group, etc.

Zydus Lifesciences Limited (formerly Cadila Healthcare Limited) is a leading Indian multinational pharmaceutical company. Specializing in generics, it innovates across NCEs, biosimilars, vaccines, and niche technologies. With global operations and 35 manufacturing facilities, the company is headquartered in Gujarat, India.

Zydus offers cost-effective and high-quality pharmaceutical products, including Paternia XT Tablet, a nutritional supplement for male fertility enhancement.